The FDA has marked today’s international Rare Disease Day with a number of measures to promote research and patient participation in policy and research.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh